NS-398: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:NS-398_molecule_spacefill.png|NS-398 molecule spacefill | |||
</gallery> | |||
Latest revision as of 00:38, 27 February 2025
NS-398 is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2. It is often used in scientific research to investigate the role of COX-2 in various diseases and conditions.
History[edit]
NS-398 was first synthesized in the 1990s as part of a research effort to develop NSAIDs that selectively inhibit COX-2, in order to reduce the gastrointestinal side effects associated with non-selective NSAIDs.
Pharmacology[edit]
NS-398 selectively inhibits COX-2, an enzyme that plays a key role in the inflammatory response. By inhibiting COX-2, NS-398 reduces the production of prostaglandins, which are chemicals that promote inflammation, pain, and fever. Unlike non-selective NSAIDs, NS-398 does not inhibit COX-1, an enzyme that protects the stomach lining from the corrosive effects of stomach acid.
Uses[edit]
NS-398 is primarily used in scientific research to investigate the role of COX-2 in various diseases and conditions. For example, it has been used to study the role of COX-2 in cancer, arthritis, and neurodegenerative diseases.
Side Effects[edit]
As a selective COX-2 inhibitor, NS-398 is expected to have fewer gastrointestinal side effects than non-selective NSAIDs. However, like all drugs, it may have side effects. The specific side effects of NS-398 are not well-documented, as it is not used clinically.


